Clinical Trials · NCT02597049
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 424
- Start date
- Nov 2015
- Locations
- 41 sites, 9 countries
- Primary endpoint
- Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Weeks (Treatment-regimen Estimand)